Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVN-001 in Japanese patients with CML
NCT06787144Phase 1Recruiting
- Sponsor
- Enliven Therapeutics
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of relcobatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Enliven Therapeutics. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Incidence of Adverse Events at 3 years and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
relcobatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06787144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787144.